A Phase 4 interventional study of Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein and Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein in High Caries Risk Patients, sponsored by Cairo University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-02-05.
Sponsored by Cairo University · Phase 4, Interventional, and Prevention
Two different Fluoride varnish systems(Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride (CPC) and conventional fluoride) will be applied to high caries risk patients to assess their clinical effects on plaque accumulation and plaque bacterial count .
Preoperative steps:
clinical steps:
Each participant will be assessed for plaque retention using plaque index and Standardized photography and image analysis to disclosed dental plaque, and plaque bacterial count using culture media sensitive for mutans streptococci (MS) in the following intervals:
Cairo University is the lead sponsor of 4,780 studies on the registry; 1,427 are open to participants now.
Of its 36 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with good general state of health.
Exclusion Criteria:
Patients with disabilities, systemic disease or severe medical conditions.
Varnish containing Fluoride, Chlorhexidine and Cetylpyridinium Chloride (Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein) will applied to this group once at the beginning of the study.Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
Drug: Cervitec F, Ivoclar Vivadent - Schaan Liechtenstein
Varnish containing Fluoride (Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein). will applied to this group once at the beginning of the study. Plaque and bacterial count will be evaluated at intervals 2 weeks,4 weeks,12 weeks, and 24 weeks.
Drug: Fluor Protector, Ivoclar Vivadent - Schaan Liechtenstein
Fluoride varnish containing Chlorhexidine and Cetylpyridinium Chloride
Conventional Fluoride varnish
Plaque Retention
Checked using a disclosing agent by Silness and Löe Dental Plaque index
Time frame: Patient will be evaluated at 2nd week of the study in the morning before teeth brushing.
Plaque Retention
Checked using a disclosing agent by Silness and Löe Dental Plaque index
Time frame: Patient will be evaluated at 4th week of the study in the morning before teeth brushing.
Plaque Retention
Checked using a disclosing agent by Silness and Löe Dental Plaque index
Time frame: Patient will be evaluated at 12th week of the study in the morning before teeth brushing.
Plaque Retention
Checked using a disclosing agent by Silness and Löe Dental Plaque index
Time frame: Patient will be evaluated at 24th week of the study in the morning before teeth brushing.
Plaque bacterial count
Culture media for mutans streptococci (MS) is used to measure (MS) count in collected plaque samples
Time frame: Patient will be evaluated at 2nd, 4th, 12th and 24th week of the study in the morning before teeth brushing.
Plan to share: No
No publications or documents are linked to this record.
This study is status unknown, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cairo University